Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection

Bruguera, 2012, Documento de posicionamiento de la Societat Catalana de Digestologia: tratamiento tripIle de la hepatitis crónica C genotipo 1, Gastroenterol Hepatol, 35, 667, 10.1016/j.gastrohep.2012.03.005 Agencia Española de Medicamentos y Productos Sanitarios, 2012 McHutchinson, 2009, Telaprevir and perginterferon and ribavirin for chronic HCV genotype 1 infection, N Engl J Med, 360, 1827, 10.1056/NEJMoa0806104 Hézode, 2009, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection, N Engl J Med, 360, 1839, 10.1056/NEJMoa0807650 McHutchinson, 2010, Telaprevir for previously treated chronic HCV infection, N Eng J Med, 362, 1292, 10.1056/NEJMoa0908014 Jacobson, 2011, Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med, 364, 2405, 10.1056/NEJMoa1012912 Zeuzem, 2011, Telaprevir for retreatment of HCV infection, N Engl J Med, 364, 2417, 10.1056/NEJMoa1013086 Sherman, 2011, Response-guided telaprevir combination treatment for hepatitis C virus infection, N Engl J Med, 365, 1014, 10.1056/NEJMoa1014463 Kwo, 2010, Efficacy of Boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial, Lancet, 376, 705, 10.1016/S0140-6736(10)60934-8 Poordad, 2011, Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med, 364, 1195, 10.1056/NEJMoa1010494 Bacon, 2011, Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med, 364, 1207, 10.1056/NEJMoa1009482 Virolés, 2015, La finalización precoz del tratamiento triple con telaprevir de la hepatitis crónica C por efecto adverso grave no presupone necesariamente el fracaso del tratamiento, Gastroenterol Hepatol, 38, 78, 10.1016/j.gastrohep.2014.04.003 Berg, 2011, Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peg-inf/ribavirin failure: post-hoc analysis of the phase III REALIZE study, Hepatology, 54, 375A Quiles, 2014, Valor de la genética en la era de la terapia triple frente al virus de la hepatitis C, Gastroenterol Hepatol, 37, 427, 10.1016/j.gastrohep.2014.04.004 Askarieh, 2010, Systemic and intrahepatic interferon-gamma-inducible protein 10-kDa predicts first phase decline in hepatitis C virus RNA and overall response to therapy in chronic hepatitis C, Hepatology, 51, 1523, 10.1002/hep.23509 Lagging, 2011, Response prediction in chronic hepatitis C by assessment of PI-10 and IL28B-related single nucleotide polymorphisms, PLoS ONE, 6, e17232, 10.1371/journal.pone.0017232